AtriCure (NASDAQ:ATRC) Raised to “Strong-Buy” at UBS Group

AtriCure (NASDAQ:ATRC) was upgraded by equities researchers at UBS Group to a “strong-buy” rating in a note issued to investors on Tuesday,Zacks.com reports.

ATRC has been the topic of several other reports. Wall Street Zen cut shares of AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Zacks Research raised shares of AtriCure from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 24th. Freedom Capital upgraded shares of AtriCure to a “strong-buy” rating in a research note on Wednesday, April 1st. Weiss Ratings raised shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a report on Tuesday. Finally, Raymond James Financial set a $52.00 price objective on shares of AtriCure in a research note on Tuesday, July 21st. Three analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $48.50.

AtriCure Stock Up 2.9%

NASDAQ:ATRC opened at $40.89 on Tuesday. AtriCure has a twelve month low of $25.36 and a twelve month high of $43.18. The company has a market cap of $2.08 billion, a price-to-earnings ratio of 194.72 and a beta of 1.24. The stock has a fifty day simple moving average of $30.68 and a 200-day simple moving average of $31.30. The company has a current ratio of 4.22, a quick ratio of 3.18 and a debt-to-equity ratio of 0.14.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The firm had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same period in the previous year, the firm earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Analysts anticipate that AtriCure will post 0.2 EPS for the current year.

Insider Buying and Selling

In other AtriCure news, Director Karen Prange sold 3,000 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $28.65, for a total value of $85,950.00. Following the completion of the transaction, the director directly owned 26,373 shares in the company, valued at approximately $755,586.45. The trade was a 10.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 4.00% of the company’s stock.

Institutional Investors Weigh In On AtriCure

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Geneos Wealth Management Inc. purchased a new position in AtriCure in the second quarter worth $37,000. Harbor Investment Advisory LLC purchased a new stake in shares of AtriCure during the 2nd quarter valued at $40,000. Smartleaf Asset Management LLC lifted its holdings in shares of AtriCure by 59.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 429 shares during the last quarter. Fifth Third Bancorp acquired a new stake in shares of AtriCure in the 1st quarter worth $51,000. Finally, Global Retirement Partners LLC acquired a new stake in shares of AtriCure in the 4th quarter worth $73,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.